Literature DB >> 17893910

Microsatellite unstable colorectal cancer cell lines with truncating TGFbetaRII mutations remain sensitive to endogenous TGFbeta.

K Baker1, P Raut, J R Jass.   

Abstract

Disruptions to the TGFbeta signalling pathway have been implicated in most human adenocarcinomas. As cancers progress, many acquire resistance to the growth-suppressing properties of TGFbeta while retaining sensitivity to its tumour-promoting effects. Microsatellite unstable colorectal cancers (MSI-H CRCs) possess truncating mutations in the type II TGFbeta receptor (TGFbetaRII) gene that have been assumed to render these tumours insensitive to TGFbeta. However, numerous reports of TGFbetaRII bypass exist and this study was thus undertaken in order to clarify the true extent of TGFbeta sensitivity in MSI-H CRCs. Using stimulation with exogenous TGFbeta, we demonstrated that, while MSI-H CRCs are capable of binding soluble TGFbeta, two out of three cell lines examined remain refractory to its signalling effects. In contrast, use of a specific inhibitor of the type I TGFbeta receptor (TGFbetaRI) revealed that all remain sensitive to signalling by endogenously produced TGFbeta. Specifically, autocrine signalling via TGFbetaRI mediates constitutive activation of Smad2 as well as repression of Erk signalling. Real-time PCR confirmed that these effects are sufficient to affect the expression level of various TGFbeta-modulated genes. An invasion assay revealed that autocrine TGFbetaRI signalling also promotes the invasion capacity of MSI-H CRCs to an extent similar to that seen in their non-MSI-H counterparts. Independent TGFbetaRI signalling, however, has no effect on the rate of proliferation of MSI-H CRC cells. Together, these results demonstrate that MSI-H CRC cell lines are not completely refractory to TGFbeta, despite lacking functional TGFbetaRII. In addition to clarifying the true consequences of natural TGFbetaRII loss and the independent function of TGFbetaRI, our results highlight the selective nature of TGFbeta resistance developed by cancers. Copyright 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17893910     DOI: 10.1002/path.2235

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  7 in total

Review 1.  Transforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer.

Authors:  Barbara Jung; Jonas J Staudacher; Daniel Beauchamp
Journal:  Gastroenterology       Date:  2016-10-20       Impact factor: 22.682

2.  Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors.

Authors:  Inti Zlobec; Alessandro Lugli
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

3.  Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing.

Authors:  Liying Zhang
Journal:  J Mol Diagn       Date:  2008-06-13       Impact factor: 5.568

4.  Clinicopathological Characterization and Prognostic Implication of SMAD4 Expression in Colorectal Carcinoma.

Authors:  Seung-Yeon Yoo; Ji-Ae Lee; Yunjoo Shin; Nam-Yun Cho; Jeong Mo Bae; Gyeong Hoon Kang
Journal:  J Pathol Transl Med       Date:  2019-06-24

Review 5.  Autocrine TGF-β in Cancer: Review of the Literature and Caveats in Experimental Analysis.

Authors:  Hendrik Ungefroren
Journal:  Int J Mol Sci       Date:  2021-01-19       Impact factor: 5.923

6.  Transforming growth factor beta receptor 2 (TGFBR2) changes sialylation in the microsatellite unstable (MSI) Colorectal cancer cell line HCT116.

Authors:  Jennifer Lee; Seda Ballikaya; Kai Schönig; Claudia R Ball; Hanno Glimm; Juergen Kopitz; Johannes Gebert
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

7.  Specific microRNA-mRNA Regulatory Network of Colon Cancer Invasion Mediated by Tissue Kallikrein-Related Peptidase 6.

Authors:  Earlphia Sells; Ritu Pandey; Hwudaurw Chen; Bethany A Skovan; Haiyan Cui; Natalia A Ignatenko
Journal:  Neoplasia       Date:  2017-04-18       Impact factor: 5.715

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.